#pt141 PT-141 (Bremelanotide) Peptide PT-141 for Men and Women:

References View all 9 references + Sikiri, P., et al

In a double-blind phase 2 trial, 157 recruited vitiligo patients were randomized, in a 1:1:1:1:1 ratio, to receive topical ruxolitinib cream 1.5% BID, 1.5% QD, 0.5% QD, 0.15% QD, or a vehicle for 24 weeks, with the result showing considerably decreased CXCL9 and CXCL10 expression in 1.5% BID and 1.5% QD groups, and more individuals in groups receiving ruxolitinib cream 1.5% BID, 1.5% QD and 0.5% QD achieving F-VASI50, during which 1.5% BID group produced the highest responses in F-VASI50 (58%), F-VASI75 (52%), and F-VASI90 (33%)

A hypoallergenic body wash helps remove skin impurities thoroughly with deep hydration

Both groups lost weight early, but separation emerged between weeks 48

Improves Skin Texture and Makes Your Skin Glow.Controls Pigmentation, Dark Spot and Pimples